Targets › OPRD1
17 programs from 17 companies in 64 trials: 25 Phase 2, 16 Phase 4, 12 Phase 1, 11 Phase 3; Psychiatry, Other, Metabolic and endocrine; next expected readout Nov 2026.
G protein-coupled receptor that functions as a receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. (UniProt, P41143)
Open in Phaseline: the race on OPRD1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Pennsylvania | 2-[18F]-FA Voltage-gated calcium channel modulator | CHRNA4, OPRK1, OPRD1, OPRM1, UL51, ADRA2A, ADRA2C, ADRA2B, Ion channels, CACNB4, CACNB2, CACNB1, CACNB3, TNF, SLC6A4, HTR2A, HTR2C, FKBP1A, CD86, CD80, PDE4A, PDE4D, PDE4B, PDE4C, PDE3A, CHRNB2, STN | Phase 4 | Alcohol Use Disorder; Acute Kidney Injury; Insomnia; Giant Cell Arteritis … | Nov 2026 |
| Zhujiang Hospital | Anrikefon Delta opioid receptor agonist | OPRD1 | Phase 4 | Pruritus Chronic | Dec 2027 |
| Currax Pharmaceuticals | Naltrexone Opioid receptors; mu/kappa/delta antagonist | OPRK1, OPRD1, OPRM1 | Phase 4 | Obesity | Jan 2029 |
| Middle Tennessee Research Institute | Naloxone Opioid receptors; mu/kappa/delta antagonist | OPRK1, OPRD1, OPRM1 | Phase 4 | Low Back Pain | – |
| University of Colorado, Denver | Naloxone Opioid receptors; mu/kappa/delta antagonist | OPRK1, OPRD1, OPRM1 | Phase 4 | Harm Reduction | – |
| Friends Research Institute, Inc. | Naloxone Opioid receptors; mu/kappa/delta antagonist | OPRK1, OPRD1, OPRM1 | Phase 4 | Opioid Use Disorder | – |
| Pouya Azar | Naloxone Hydrochloride Opioid receptors; mu/kappa/delta antagonist | OPRK1, OPRD1, OPRM1 | Phase 4 | Opioid Use Disorder | – |
| University of Maryland, Baltimore | Naloxone Opioid receptors; mu/kappa/delta antagonist | OPRK1, OPRD1, OPRM1 | Phase 3 | Opioid Use Disorder; Pain | Nov 2026 |
| Adneuris Therapeutics | Cebranopadol Nociceptin receptor agonist; Opioid receptors; mu/kappa/delta agonist | OPRL1, OPRK1, OPRD1, OPRM1 | Phase 3 | Pain; Chronic Pain | Jan 2027 |
| Trevi Therapeutics | Nalbuphine Opioid receptors; mu/kappa/delta agonist | OPRK1, OPRD1, OPRM1 | Phase 3 | Idiopathic Pulmonary Fibrosis; Refractory Chronic Cough; Laryngoscopy; Postoperative Pain, Acute … | Aug 2027 |
| AgelessRx | Naltrexone Opioid receptors; mu/kappa/delta antagonist | OPRK1, OPRD1, OPRM1 | Phase 3 | Healthspan Improvement; Longevity; Human Immunodeficiency Virus; Obesity; Drug … | – |
| Alkermes | Samidorphan Mu opioid receptor antagonist; Kappa opioid receptor partial agonist; Delta opioid receptor partial agonist | OPRM1, OPRK1, OPRD1 | Phase 3 | Schizophrenia | – |
| Medical University of Lublin | Naltrexone Hydrochloride Opioid receptors; mu/kappa/delta antagonist | OPRK1, OPRD1, OPRM1 | Phase 2 | Vulvodynia | Dec 2026 |
| New York State Psychiatric Institute | Naloxone Opioid receptors; mu/kappa/delta antagonist | OPRK1, OPRD1, OPRM1 | Phase 2 | Opioid-use Disorder | Jan 2027 |
| University of British Columbia | Naloxone Opioid receptors; mu/kappa/delta antagonist | OPRK1, OPRD1, OPRM1 | Phase 2 | Opioid-use Disorder | Dec 2027 |
| ReacX Pharmaceuticals | Nalmefene Mu opioid receptor antagonist; Delta opioid receptor antagonist; Kappa opioid receptor partial agonist | OPRM1, OPRD1, OPRK1 | Phase 1 | Opioid Abuse and Addiction; Behavioural Addiction | Dec 2026 |
| Akyso Therapeutics | Naltrexone Opioid receptors; mu/kappa/delta antagonist | OPRK1, OPRD1, OPRM1 | Phase 1 | Opioid Use Disorder | Oct 2029 |
Alcohol Use Disorder (5) Opioid Use Disorder (5) Opioid-use Disorder (3) Idiopathic Pulmonary Fibrosis (2) Pain (2) Head and Neck Squamous Cell Carcinoma (2) Low Back Pain (1) Refractory Chronic Cough (1) Laryngoscopy (1) Postoperative Pain, Acute (1) Hip Fracture Surgeries (1) Acute Respiratory Distress Syndrome (1)
small molecule (14), mixed (2)
Middle Tennessee Research Institute (1) Trevi Therapeutics (1) Currax Pharmaceuticals (1) New York State Psychiatric Institute (1) University of British Columbia (1) AgelessRx (1) ReacX Pharmaceuticals (1) Akyso Therapeutics (1) University of Maryland, Baltimore (1) Zhujiang Hospital (1) Pouya Azar (1) University of Colorado, Denver (1) Friends Research Institute, Inc. (1) Adneuris Therapeutics (1) Medical University of Lublin (1) University of Pennsylvania (1) Alkermes (1)
OPRK1 (16) OPRM1 (16) OPRL1 (1) CHRNA4 (1) UL51 (1) ADRA2A (1) ADRA2C (1) ADRA2B (1) Ion channels (1) CACNB4 (1) CACNB2 (1) CACNB1 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.